Neuromyelitis Optica Treatment Analysis of 36 Patients

Neuromyelitis Optica Treatment Analysis of 36 Patients

Author Bichuetti, Denis Bernardi Autor UNIFESP Google Scholar
Lobato de Oliveira, Enedina Maria Autor UNIFESP Google Scholar
Oliveira, Daniel May Autor UNIFESP Google Scholar
Souza, Nilton Amorin de Autor UNIFESP Google Scholar
Gabbai, Alberto Alain Autor UNIFESP Google Scholar
Institution Universidade Federal de São Paulo (UNIFESP)
Abstract Objective: To analyze treatment response in Brazilian patients with neuromyelitis optica.Design: Retrospective review.Setting: Neuroimmunology Clinic of the Federal University of Sao Paulo, Sao Paulo, Brazil.Patients: Thirty-six patients with relapsing-remitting optic-spinal disease; long, extending spinal cord lesions; and brain magnetic resonance images not meeting Barkhof criteria for multiple sclerosis, thus fulfilling the 1999 and 2006 criteria for neuromyelitis optica. Patients were followed up from 1994 to 2007.Main Outcome Measures: Relapses and accumulation of disability.Results: Mean follow-up time was 47.2 months and mean age at onset was 32.3 years. Sixty-four treatments were implemented in 36 patients, which included interferon beta, methotrexate, cyclophosphamide, prednisone, and azathioprine solely or plus prednisone. Patients who were treated with azathioprine or azathioprine with prednisone had a reduction in the occurrence of relapses and Expanded Disability Severity Scale score stabilization, as opposed to patients who received other treatments. Of the 4 patients who died, only 1 had received azathioprine treatment.Conclusion: Azathioprine as monotherapy or with prednisone seems to have reduced the relapse frequency and halted disability progression in the majority of patients treated, with minor and manageable adverse effects.
Language English
Sponsor Bayer Schering
Biogen Idec
Merck Serono
Teva Pharmaceuticals
Date 2010-09-01
Published in Archives Of Neurology. Chicago: Amer Medical Assoc, v. 67, n. 9, p. 1131-1136, 2010.
ISSN 0003-9942 (Sherpa/Romeo, impact factor)
Publisher Amer Medical Assoc
Extent 1131-1136
Access rights Open access Open Access
Type Article
Web of Science ID WOS:000282102800014

Show full item record


File Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)




My Account